(Q51373947)

English

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

scientific article published in September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

1 reference

based on heuristic

inferred from title

author name string

L Olansky

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

C Reasner

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

T L Seck

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

D E Williams-Herman

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

M Chen

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

L Terranella

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

A Mehta

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

K D Kaufman

8

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

B J Goldstein

9

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

publication date

1 September 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

13

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

9

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

841-849

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Clinical inertia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Diabetes in urban African-Americans. IX. Provider adherence to management protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

GLP-1: broadening the incretin concept to involve gut motility

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Sitagliptin: a novel drug for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01416.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01416.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

release_7fyyh7gjbfdzngbc7mplebqer4

1 reference

https://api.fatcat.wiki/v0/release/7fyyh7gjbfdzngbc7mplebqer4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21535346

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51373947&oldid=1843367862"